Drug Product
Company Overview
About
Adelco SA is a pharmaceutical CDMO offering comprehensive services.
Key Expertise
Specialized in Gene Therapy, Cell Therapy, mRNA
Therapeutic Areas
Oncology
Hematology
Quick Facts
HQ:Greece
Founded:1994
Employees:2,864
Capabilities & Services
Core Capabilities
- Oral Solid Dose
- Solid Dose Manufacturing
- Formulation Development
Types of Organization
GMP Manufacturing
Quality Systems
Regulatory Support
Dosage Forms
Lyophilized (Freeze-Dried)
Sterile Injectable
Containment Capabilities
OEB 4 (1-10 µg/m³)
Production Scales
Phase III Clinical Trials
Commercial Scale
Clinical
Markets Served
Global
Regulatory Approvals
Drug Approval L4QA4I
PMDA · #APR-C04GCDEI · 2018-10-01
Drug Approval CH8BSG
FDA · #APR-45RCSSDV · 2018-02-01
Certifications
FDA Registration
U.S. Food and Drug Administration
Cert #: CERT-PLCLDMTT
Issued: 2020-05-10
Expires: 2025-08-07
WHO GMP
World Health Organization
Cert #: CERT-41ICB6OC
Issued: 2020-07-19
Expires: 2025-12-23
Health Canada GMP
Health Canada
Cert #: CERT-0OC5L2ZI
Issued: 2020-11-09
Expires: 2025-02-14
Loading CDMO intelligence...
Key facts about Adelco SA
- Adelco SA is headquartered in Greece.
- Adelco SA was founded in 1994.
- Adelco SA has 2,864 employees.
- Adelco SA's capabilities include Oral Solid Dose, Solid Dose Manufacturing and Formulation Development.
Find CDMOs like Adelco SA
Directory pages this company appears in, each with the full list of matching manufacturers.